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Abstract
Background: Clostridium difficile is the most common cause of nosocomial infectious diarrhea in the United States.
However, recent reports have documented that C. difficile infections (CDIs) are occurring among patients without
traditional risk factors. The purpose of this study was to examine the epidemiology of CA-CDI, by estimating the
incidence of CA-CDI and HA-CDI, identifying patient-related risk factors for CA-CDI, and describing adverse health
outcomes of CA-CDI.
Methods: We conducted a population-based, retrospective, nested, case-control study within the University of
Iowa Wellmark Data Repository from January 2004 to December 2007. We identified persons with CDI, determined
whether infection was community-associated (CA) or hospital-acquired (HA), and calculated incidence rates. We
collected demographic, clinical, and pharmacologic information for CA-CDI cases and controls (i.e., persons without
CDI). We used conditional logistic regression to estimate the odds ratios (ORs) for potential risk factors for CA-CDI.
Results: The incidence rates for CA-CDI and HA-CDI were 11.16 and 12.1 cases per 100,000 person-years,
respectively. CA-CDI cases were more likely than controls to receive antimicrobials (adjusted OR, 6.09 [95% CI 4.59-
8.08]) and gastric acid suppressants (adjusted OR, 2.30 [95% CI 1.56-3.39]) in the 180 days before diagnosis.
Controlling for other covariates, increased risk for CA-CDI was associated with use of beta-lactam/beta-lactamase
inhibitors, cephalosporins, clindamycin, fluoroquinolones, macrolides, and penicillins. However, 27% of CA-CDI cases
did not receive antimicrobials in the 180 days before their diagnoses, and 17% did not have any traditional risk
factors for CDI.
Conclusions: Our study documented that the epidemiology of CDI is changing, with CA-CDI occurring in
populations not traditionally considered “high-risk” for the disease. Clinicians should consider this diagnosis and
obtain appropriate diagnostic testing for outpatients with persistent or severe diarrhea who have even remote
antimicrobial exposure.
Background
Clostridium difficile is the most common cause of noso-
comial infectious diarrhea in the United States. Several
reports indicate that the incidence and the severity of
C. difficile infections (CDI) are increasing [1-3], possibly
related to the new virulent BI/NAP1 strain [4]. Investi-
gators have identified numerous risk factors for hospi-
tal-acquired CDI (HA-CDI) (e.g., antimicrobial use,
older age, underlying diseases) [5-9]. However, recent
published reports have described CDI cases in people
without traditional risk factors [10-12], including people
without recent exposures to antimicrobials. These
reports suggest that community-associated CDI (CA-
CDI) cases are occurring in persons who are younger,
have fewer comorbidities, and less exposure to health-
care than persons with HA-CDI [10-15].
Few large studies have been conducted to identify risk
factors for CDI in the community-setting, and investigators
have not determined if or to what extent the epidemiology
of CA-CDI differs from that of HA-CDI. Furthermore,
most studies of CA-CDI in the United States are based on
brief periods of voluntary surveillance in limited geographic
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areas and in targeted populations [12,15,16]. The purpose
of this study was to examine the epidemiology of CA-CDI
in a broad population. Specifically, this study estimates the
incidence of CA-CDI and HA-CDI within an employer-
based, insured population covering two states, identifies
patient-related risk factors for CA-CDI, and describes
adverse health outcomes of CA-CDI.
Methods
Design Overview
We conducted a retrospective, nested, case-control study
using the Wellmark Data Repository (Data Repository),
which is housed at the University of Iowa College of Pub-
lic Health, to identify persons with CDI from January 1,
2004 to December 31, 2007. The Data Repository is a
limited, longitudinal data set consisting of de-identified
healthcare claims for members and their covered family
members who are fully-insured through policies under-
written by Wellmark, the largest provider of health insur-
ance in Iowa and South Dakota. This study was approved
by the University of Iowa Institutional Review Board.
We examined insurance claims for inpatient, outpatient,
home health, extended care/skilled nursing, and outpatient
pharmacy healthcare services provided to members with
health and prescription drug coverage. These data
included insurance coverage, demographic information,
diagnosis codes, procedure codes, dates of service and,
outpatient pharmacy data including fill dates and drug-
days supplied.
Identification of Case and Control Patients
We identified cases as persons with a primary or second-
ary diagnosis of ICD-9 code 008.45 for ‘Infection due to
Clostridium difficile’ listed on an inpatient or outpatient
insurance claim. Case subjects were required to have a
minimum of 12 months of continuous health and phar-
macy insurance coverage before their diagnosis and not
have a history of healthcare claims from a long-term care
facility during the 6 months before their diagnoses. Only
the first C. difficile diagnosis was included. The diagnosis
date was defined as the date on which the ICD-9 code for
CDI first appeared on a claim.
A case of CA-CDI either had: (1) a diagnosis of CDI in
the outpatient setting with no history of hospital discharge
in the 12 weeks before diagnosis, or (2) a primary diagnosis
upon hospital admission and no history of hospital dis-
charge in the 12 weeks before diagnosis. A case of HA-CDI
had either: (1) a secondary diagnosis during hospitalization;
(2) a primary diagnosis upon admission to a hospital with a
history of hospital discharge in the 4 weeks before diagno-
sis; or, (3) a diagnosis of CDI in the outpatient setting with
a history of hospital discharge in the 4 weeks before diag-
nosis. All other cases were defined as indeterminate (i.e.,
did not meet the definitions of CA-CDI or HA-CDI).
For each CA-CDI case subject, ten control subjects were
randomly selected. Members were eligible to serve as con-
trols if they met inclusion criteria for cases (i.e., minimum
of 12 months of continuous health and pharmacy insur-
ance coverage and no history of healthcare claims from a
long-term care facility in the prior 6 months), but had not
been diagnosed with CDI on or before the date of diagno-
sis for a corresponding case [17]. A member could be a
control subject and subsequently a case subject if CDI was
diagnosed later. The index date for each control was the
diagnosis date for the matched case. No further matching
criteria were imposed.
Assessment of Exposures to Antimicrobial Agents and
Gastric Acid Suppressants among CA-CDI Cases and
Controls
We examined outpatient prescription use of antimicrobials
among CA-CDI cases and controls in the 180 days before
the diagnosis or index date. Prescription medications were
identified through National Drug Codes (NDCs) on outpa-
tient prescription drug claims. We examined exposure to
specific antimicrobial classes or agents (aminoglycosides,
beta-lactam/beta-lactamase inhibitors, cephalosporins,
clindamycin, fluoroquinolones, macrolides, penicillins, sul-
fonamides, tetracyclines, and intravenous vancomycin),
the total number of different antimicrobial agents received,
and the timing of antimicrobial use in relation to the diag-
nosis or index dates. We categorized the timing of the
subjects’ most recent antimicrobial exposures as use dur-
ing the following mutually exclusive intervals before the
diagnosis or index dates (calculated from the last prescrip-
tion’s fill date and the days of antimicrobial supplied): 1 to
30 days, 31 to 60 days, 61 to 90 days, 91 to 120 days, 121
to 150 days, and 151 to 180 days. We did not examine use
of topical or ophthalmic antimicrobials. In addition, we
did not include use of metronidazole or oral vancomycin
as possible risk factors, because they are used to treat CDI.
We also examined use of prescription gastric acid sup-
pressants–proton pump inhibitors and histamine-2
receptor antagonists. Proton pump inhibitors included
lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Histamine-2 receptor antagonists included cimetidine,
and ranitidine. We categorized use of these medications
as “never-used” or “ever-used” in the 180 days before
the diagnosis or index dates.
Assessment of Comorbidity and Healthcare Utilization
among CA-CDI Cases and Controls
We used the Charlson Comorbidity Index to measure
underlying comorbidity among CA-CDI cases and their
controls [18,19]. Charlson comorbid conditions were
considered “present” if the corresponding ICD-9 code
was listed as a primary or secondary diagnosis on one
inpatient claim or on two outpatient claims occurring
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30 or more days apart in the year before the diagnosis or
index dates [20]. We identified hospitalizations in the
year before the diagnosis or index dates. We also deter-
mined whether or not patients had inflammatory bowel
disease (i.e., Crohn’s disease [ICD-9 codes: 555.0-555.9)
and ulcerative colitis [ICD-9 codes: 556-556.9]).
Identification of Adverse Outcomes among CA-CDI Cases
Potential adverse outcomes following CA-CDI included
colectomies, subsequent hospitalizations for CDI, and
relapse of infection. We determined whether persons with
CA-CDI had colectomies (ICD-9 procedure codes: partial/
subtotal [45.79], cecal [45.72], left colon [45.75], multiple
segmental [45.71], right colon [45.73], sigmoid [45.76], sub-
total [45.8], and transverse colon [45.74]) during the 180
days following diagnosis [21]. We defined hospitalization
related to CDI as an admission with a primary diagnosis of
CDI occurring on the date of diagnosis of CA-CDI or dur-
ing the following 8 weeks [22]. We considered claims for
metronidazole or oral vancomycin prescriptions submitted
after claims for the initial therapy and within 180 days of
the diagnosis date to be markers for CDI recurrence or
relapse.
Statistical Analyses
The incidence rates for CA-CDI and HA-CDI were the
number of incident cases per 100,000 person-years of
observation time. The denominator data were calculated
based on duration of insurance coverage for each person
in the Data Repository population for each year.
We calculated summary statistics for demographic
characteristics, healthcare utilization, comorbid condi-
tions, and medication among CA-CDI cases and controls.
We used conditional logistic regression to estimate odds
ratios (ORs) for the associations between CA-CDI and
any antimicrobial use, use of individual antimicrobials,
timing of antimicrobial use, number of antimicrobial
agents prescribed, and use of gastric acid suppressants,
while adjusting for covariates including comorbidity,
inflammatory bowel disease (IBD), hospitalizations, age
(in categories), and gender. In separate models, we esti-
mated the ORs for the associations between CA-CDI and
use of each antimicrobial class and also CA-CDI and the
number of different antimicrobials. Because aminoglyco-
sides and intravenous vancomycin were used infre-
quently, we excluded them from models for individual
agents. When we assessed timing of antimicrobial use,
we considered ‘no antimicrobial use in the prior 180
days’ to be the reference group. We used SAS version 9.2
(SAS Institute Inc., Cary, NC) for all analyses.
Results
During the study period, we identified 684 cases of CDI,
of which, 304 were CA-CDI, 338 were HA-CDI, and 42
were indeterminate CDI. The overall incidence rates for
CA-CDI and HA-CDI were 11.16 and 12.41 cases per
100,000 person-years, respectively. Year-specific inci-
dence rates are shown in Table 1.
The case-control study included 304 CA-CDI cases
and 3040 controls. Baseline characteristics of case and
control patients are shown in Table 2. The majority of
the study subjects were between the ages of 19 and 64
years (76% of cases and 69% of controls), but CA-CDI
cases were significantly older than control subjects. CA-
CDI cases (11%) were more likely than controls (3%) to
be hospitalized in the previous year. Cases had more
Charlson comorbidities, although only 11% of cases and
4% of controls had Charlson indices of 1 or greater.
CA-CDI cases were more likely than controls to receive
antimicrobials in the previous 180 days (adjusted OR
6.09, 95% CI 4.59-8.08) (Table 2). After adjusting for all
covariates including antimicrobial use; age 19 years and
older (with ≤ 18 years as the reference group), IBD, and
gastric acid suppressant use significantly increased the
risk of CA-CDI. Eighteen percent of CA-CDI cases and
5% of controls received gastric acid suppressants in the
180 days before their diagnosis or index dates (adjusted
OR 2.30, 95% CI 1.56-3.39) (Table 2), and 84% of persons
with CA-CDI who received gastric acid suppressants also
received one or more antimicrobial agents (data not
shown).
After controlling for other covariates, increased risk
for CA-CDI was associated with use of beta-lactam/
beta-lactamase inhibitors, cephalosporins, clindamycin,
fluoroquinolones, macrolides, and penicillins (Table 3).
The risk for CA-CDI was highest for antimicrobial use
during the 30-days before diagnosis and remained signif-
icantly elevated for antimicrobial use as early as 150
days before diagnosis (Table 3). Finally, each antimicro-
bial agent prescribed significantly increased the risk for
CA-CDI (Table 3).
We performed a sensitivity analysis to examine the rela-
tionship between risk factors and onset of CA-CDI after
we redefined the diagnosis date as the date of the first: (1)
CDI diagnosis code, (2) prescription for oral vancomycin
or antimotility medication, or (3) diagnosis code for non-
specific diarrheal disease. When we utilized this approach,
122 cases retained their original diagnosis dates based on
ICD-9 codes, while 177 cases had revised diagnosis dates
based on prescription medication use or diagnosis of diar-
rheal disease. The results of this analysis, which included
cases with original and revised diagnosis dates and their
controls, were essentially the same as those reported in
Table 3.
No one with CA-CDI required a colectomy. Seventy-
seven CA-CDI cases were admitted (79 admissions) with
the primary diagnosis of ICD-9 code 008.45 entered on
the diagnosis date or within 8 weeks, for a hospitalization
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rate of 25.3%. Of the 77 first-time admissions, sixty-three
(81.8%) occurred on the date of diagnosis, 10 (12.7%)
occurred 1 day after the CDI diagnosis, and 1 each
occurred 4, 20, 24, and 30 days after diagnosis. The mean
time between the diagnosis of CA-CDI and hospital
admission was 1.14 days (Median: 0 days; Std. Dev: 4.87).
Of 304 CA-CDI cases, 21 (6.9%) received at least one
additional prescription for metronidazole or oral vanco-
mycin after their initial therapy; 12 cases received 1
additional prescription for metronidazole or oral vanco-
mycin, 3 received 2 prescriptions, 4 received 3 prescrip-
tions, and, 2 received 4 prescriptions. Of these cases,
76% were retreated within 30 days of their CDI diag-
noses and 90% were retreated within 60 days.
Discussion
Our results demonstrate that CA-CDI is occurring
among populations not traditionally considered ‘high-
risk’ (i.e., younger people, people without underlying ill-
ness, people not exposed to hospitals or antimicrobials).
In fact, among our relatively young study population,
the incidence rates of CA-CDI and HA-CDI were simi-
lar; 44% of all cases were community-associated.
Similar to other studies of CA-CDI, our study found
that a substantial proportion of persons with CA-CDI
did not have traditional risk factors for this infection:
27% did not receive any antimicrobials in the 180 days
before their diagnoses and 17% did not have any of the
traditional risk factors for CDI (i.e., no antimicrobial or
gastric acid suppressant exposure, no underlying illness,
and no history of hospitalization) [13,14]. The risk fac-
tors we identified for CA-CDI were similar to risk fac-
tors for HA-CDI. For example, prior antimicrobial use
was the most common risk factor, and the ‘highest-risk’
antimicrobials were similar to those commonly-asso-
ciated with HA-CDI (i.e., clindamycin, fluoroquino-
lones). Also, we found that most antimicrobials were
associated with some risk for CDI and each additional
antimicrobial agent increased the risk for CA-CDI
further. These results support calls from organizations
including the Centers for Disease Control and Preven-
tion and the Infectious Diseases Society of America for
physicians to eliminate inappropriate antimicrobial use
for both inpatients and outpatients.
Our study also found that persons exposed to antimi-
crobial agents are at risk for CA-CDI longer than
Table 1 Number of cases and incidence rates of community-associated and hospital-acquired C. difficile infection,
2004-2007
Year Total Person-years Number of CA-CDI Cases CA-CDI Incidence Rate* Number of HA-CDI Cases HA-CDI Incidence Rate*
2004 667,113 62 9.29 85 12.71
2005 673,630 84 12.47 76 11.28
2006 666,127 74 11.11 84 12.61
2007 716,265 84 11.76 93 12.98
* Incidence rates expressed as the number of cases per 100,000 person-years.
Table 2 Analysis of risk factors for community-associated C. difficile infection
Variable CA-CDI Cases (N = 304) Controls (N = 3040) Unadjusted OR (95% CI) Adjusted OR (95% CI)*
Age in Years (by category)
<18 years 45 (14.80) 814 (26.78) reference reference
19 to 49 years 125 (41.12) 1296 (42.63) 0.94 (0.74, 1.19) 1.92 (1.32, 2.78)
50 to 64 years 106 (34.87) 803 (26.41) 1.49 (1.16, 1.91) 2.36 (1.59, 3.49)
65 to 74 years 18 (5.92) 92 (3.03) 2.03 (1.21, 3.43) 3.38 (1.73, 6.57)
≥75 years 10 (3.29) 35 (1.15) 2.90 (1.43, 5.90) 2.49 (1.01, 6.12)
Gender (female) 184 (60.53) 1570 (51.64) 1.44 (1.1, 1.83) 1.24 (0.95, 1.61)
History of Hospitalization in Previous Year 33 (10.86) 103 (3.39) 3.47 (2.30, 5.23) 1.60 (0.99, 2.60)
Charlson Comorbidity Index [Mean (SD)] 0.17 (0.62) 0.05 (0.27) 2.03 (1.55, 2.64) 1.33 (0.98, 1.79)
Inflammatory Bowel Disease 12 (3.95) 4 (0.13) 30.0 (9.68, 93.02) 41.89 (11.83, 148.35)
Antimicrobial Use
None 82 (26.97) 2120 (69.74) reference reference
Any 222 (73.03) 920 (30.26) 6.12 (4.70, 7.98) 6.09 (4.59, 8.08)
Gastric Acid Suppressant Use†
None 249 (81.91) 2883 (94.84) reference reference
Any 55 (18.09) 157 (5.16) 4.07 (2.91, 5.69) 2.30 (1.56, 3.39)
NOTE. Data are number (%) of patients, unless otherwise stated.
* Adjusted for all other covariates
† Includes proton pump inhibitors and histamine-2 receptor antagonists.
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suggested by prior studies [23,24]. As expected, the
highest risk for CA-CDI in our study population was
within the first 30 days after the last antimicrobial expo-
sure. But the risk remained relatively high until 60 days
after exposure and did not return to baseline until 150-
days after exposure.
Prior studies found that gastric acid suppressant medica-
tions increase the risk for CDI, although risk estimates for
CA-CDI have varied [25-28]. In our population, use of
gastric acid suppressants increased the risk for CA-CDI,
even after controlling for use of antimicrobials and for gas-
trointestinal disease. However, most (84%) patients with
CA-CDI who took gastric acid suppressants also took anti-
microbials. Thus, although we did not find a statistical
interaction between the effects of these medication classes,
a portion of the risk attributed to gastric acid suppression
may be related to concurrent antimicrobial use.
CA-CDI had economic implications in this population.
Although persons in our study population did not require
surgical interventions for CA-CDI, approximately one out
of four cases was hospitalized, and hospitalized patients
stayed an average of 4 days. Thus, our population of
healthy persons with CA-CDI had about 308 hospital
treatment days for these infections, which added substan-
tially to the cost of care. Although the estimated relapse
rate was relatively low, 21 (6.9%) people had relapses and
received a total of 38 additional antimicrobial prescriptions
for either oral vancomycin or metronidazole. Moreover,
about half of the persons with CA-CDI had claims sub-
mitted for “non-specific diarrheal disease” in the month
before their claims for CDI. Thus, about 150 persons
experienced avoidable treatment delays and additional
out-patient visits that increased the morbidity and costs
associated with CDI.
Our study has several limitations. First, although the
ICD-9 code for CDI has reasonable sensitivity and specifi-
city for detecting CDI cases in inpatient settings [29,30], it
has not been validated as thoroughly in community set-
tings. We could not validate the coding in our data set
because we did not have access to the patients’ medical
records. Future studies are needed to validate ICD-9 code
008.45 in community settings. Moreover, we could not
determine either the date symptoms first occurred or the
date on which C. difficile testing occurred. Rather, as
noted previously, we had to define the date of CDI diagno-
sis based on the date the ICD-9 code 008.45 first appeared
on insurance claims. Second, this identification strategy is
contingent upon patients being tested for CDI and diag-
nosed in a clinical setting, thus we may have underesti-
mated the true burden of CA-CDI. Third, we most likely
underestimated the use of gastric acid suppressants
because patients may purchase these medications over-
the-counter. However, we presume that misclassification
would be nondifferential and could attenuate the
Table 3 Association between antimicrobial use in the previous 180 days and community-associated C. difficile
infection
CA-CDI Cases Controls Unadjusted OR Adjusted OR
(N = 304) (N = 3040) (95% CI) (95% CI)*
Antimicrobial Drug/Class†
Beta-lactam/beta-lactamase inhibitors 46 (15.13) 95 (3.12) 5.58 (3.79, 8.20) 5.10 (3.26, 8.00)
Cephalosporins 75 (24.67) 230 (7.57) 4.06 (3.02, 5.47) 3.11 (2.17, 4.45)
Clindamycin 35 (11.51) 26 (0.86) 15.65 (9.09, 26.95) 13.00 (7.03, 24.04)
Fluoroquinolones 67 (22.04) 94 (3.09) 8.33 (5.94, 11.67) 4.91 (3.28, 7.35)
Macrolides 61 (20.07) 300 (9.87) 2.27 (1.68, 3.07) 2.19 (1.54, 3.11)
Penicillins 50 (16.45) 291 (9.57) 1.86 (1.34, 2.58) 1.72 (1.17, 2.54)
Sulfonamides 16 (5.26) 52 (1.71) 3.16 (1.79, 5.60) 1.58 (0.79, 3.15)
Tetracyclines 11 (3.62) 78 (2.57) 1.43 (0.75, 2.71) 0.94 (0.43, 2.04)
Timing of Antimicrobial Use
No Use 82 (26.97) 2120 (69.74) reference reference
Within 1-30 Days 141 (46.38) 304 (10.00) 12.06 (8.88, 16.36) 13.02 (9.37, 18.09)
Within 31-60 Days 36 (11.84) 148 (4.87) 6.25 (4.06, 9.63) 5.84 (3.68, 9.28)
Within 61-90 Days 15 (4.93) 151 (4.97) 2.50 (1.40, 4.47) 2.30 (1.24, 4.25)
Within 91-120 Days 17 (5.59) 144 (4.74) 2.84 (1.63, 4.93) 2.30 (1.27, 4.17)
Within 121-150 Days 9 (2.96) 97 (3.19) 2.30 (1.12, 4.73) 2.77 (1.29, 5.95)
Within 151-180 Days 4 (1.32) 76 (2.50) 1.39 (0.50, 3.91) 1.17 (0.40, 3.41)
Number of Antimicrobials [Mean (SD)] 1.26 (1.10) 0.39 (0.68) 2.72 (2.40, 3.09) 2.74 (2.38, 3.15)
NOTE. Data are presented as the number (%) of patients, unless otherwise stated.
* Adjusted for age, gender, history of hospitalization, Charlson Comorbidity Index, inflammatory bowel disease, and gastric acid suppressant use
† Antimicrobial classes were entered in a multivariable model as a series of indicator variables (i.e., ORs are adjusted for the use of other classes).
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association between these agents and CA-CDI. In addition,
prescription drug claims were included in our data set
only if they were submitted and paid. Thus, we may have
underestimated antimicrobial use if patients did not sub-
mit claims for their antimicrobial prescriptions. Fourth,
inflammatory bowel disease was a significant risk factor
for CA-CDI, but this association was based on only 12
cases and 4 controls. Also, patients with IBD often have
diarrhea. Thus, higher rates of CA-CDI among patients
with IBD than among other patients could be due to sur-
veillance bias. Finally, the persons in our population were
fully-insured through either individual or employer-based
plans. In addition, the database excluded Medicare and
Medicare Supplement Insurance coverage, so the number
of persons 65 years or older was limited to those who also
purchased commercial insurance. Thus, our results may
not be generalizable to older populations. For example,
the incidence of HA-CDI and of complications (i.e., none
of the cases underwent colectomies) in our study may be
lower than in other studies because our population was
relatively young. This may also account for the low CDI
relapse rate among our population.
We studied a young, healthy insured population and
found the incidence of CA-CDI to be equal to that of HA-
CDI, suggesting that hospital-based CDI surveillance may
substantially underestimate the incidence of this infection
in community settings. In general, the risk factors for CDI
in our study population were similar to those identified for
hospitalized populations, yet over 25% of the patients had
not been exposed to antimicrobial agents. On the other
hand, the population-attributable-risk percent for antimi-
crobial use was nearly 58% [31], indicating that over half
of the cases were related to antimicrobial use, and the risk
associated with antimicrobial agents persisted over several
months. Moreover, it seems that many cases of CA-CDI
were not diagnosed upon symptom onset, indicating that
physicians may not consider this diagnosis initially. A sub-
stantial proportion of the patients were hospitalized for
treatment, indicating that these infections were serious,
and they increased the cost of care.
Conclusions
Our study documented that the epidemiology of CDI is
changing significantly and the population at risk for this
infection is much larger than previously thought. Clini-
cians should be aware of these changes and obtain
appropriate diagnostic testing on outpatients with diar-
rhea and antimicrobial exposure, including remote expo-
sure (i.e., up to 150 days prior to disease onset). To curb
spread of C. difficile in the community setting, we must
decrease antimicrobial use among outpatients and we
must conduct further research to determine the source
of C. difficile in this setting.
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